Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATOM: Almotriptan vs Ubrogepant for Acute Treatment of Migraine
2021-001087-24Phase 4Terminated
- Sponsor
- Dansk Hovedpinecenter
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in migraine comparing Almotriptan arm with Ubrogepant arm (2 arms). Primary endpoint: Pain freedom at 2 hours. Started Mar 2021; status: terminated.
02
Drugs
almotriptanubrogepant
03
Conditions
migraine
Beyond the preview
Go deeper on 2021-001087-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001087-24.